Investigating new dermatological medications
CRS – competent partner for your dermatological product development
CRS, in particular the CRS Kiel unit, currently conducts approximately one to three clinical trials per year investigating new dermatological medications. In recent years, CRS Kiel has also successfully completed most sophisticated clinical trials including first-in-human testing of biologicals and, among others, blister induction and aspiration. All this is attributed to the advanced level of expertise and experience of the CRS Kiel team, including Abir Alatrach, MD, CRS in-house dermatologist.
CRS has particular recruitment capabilities, which are supported by a well-established and long-standing collaboration with a network of external dermatologists, with large outpatient departments, and with specialists at the dermatology department of the university hospital in Kiel. CRS proprietary database allows easy identification and rapid recruitment of volunteers, patients, as well as matched elderly controls for all kind of clinical trials in the field of dermatology.
The local medical lab partner of CRS Kiel, LKF – Laboratorium für Klinische Forschung GmbH, which is specialized and accredited for the support of clinical trials, secures a reliable and rapid turnaround of laboratory results, most of which will be supplied within six hours. This facilitates screening and review of inclusion/exclusion criteria, as well as close safety monitoring of trial participants.
Dermatological assessment techniques employed at CRS
- Scoring Atopic Dermatitis (SCORAD)
- Psoriasis Skin Severity Index (PASI)
- Overall Lesion Severity (OLS)
- Irritation, sensitisation of topical and transdermal application systems
- Skin biopsies
- Subcutaneous adipose tissue biopsies
- Blister induction and aspiration
- Skin prick test for immediate allergic reactions – type I hypersensitivity
- Eczema Area and Severity Index (EASI Score)